Home
Samsung Bioepis

Samsung Bioepis Market Share Analysis for June 2026

samsung bioepis is a biopharmaceutical company focused on increasing patient access to quality-assured medicines through the development of biosimilars.

Health > Biotechnology and Pharmaceuticals

Domainsamsungbioepis.com

Year Founded2012

Employees501 - 1000

Annual Revenue$500M - $1B

Samsung Bioepis

Samsung Bioepis (including company regionals)

samsungbioepis.com

See more website traffic and engagement information

Samsung Bioepis Revenue up to June 2026 is 500M - 1B

revenue generated by Samsung Bioepis top domains

Samsung Bioepis top domains revenue over 3 years

Revenue for Samsung Bioepis top domains

samsungbioepis.com500M - 1B

See more with Sales Intelligence

Total visits to Samsung Bioepis's top domains

Understand Samsung Bioepis market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

samsungbioepis.com14.7K

See more with Sales Intelligence

Avg. visit duration in Samsung Bioepis's top domains

Analyze Samsung Bioepis engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

samsungbioepis.com00:00:11

See more with Sales Intelligence

Avg. pageviews on Samsung Bioepis's top domains

See how Samsung Bioepis keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

samsungbioepis.com2.29

See more with Sales Intelligence

Samsung Bioepis top competitors by domain

Top similar sites in June 2026, ranked by their affinity

samsungbiologics.comCompany NameSAMSUNG BIOLOGICSEmployees1001 - 5000HQKorea, Republic of, Yeonsu-guAnnual revenue> $1BTotal visits96.2KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Samsung Bioepis

These are the website technologies, by industry, used by Samsung Bioepis top domains

Advertising (4)

Google Adsense

Conversion & Analytics (3)

Google Analytics

Mobile (2)

Meta Viewport

Audio Video Media (1)

YouTube

More Technologies

5

See all

News & Signals from Samsung Bioepis

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsSamsung Bioepis Co. partnered with Proteina Co. on Jul 9th '26.INCHEON, Korea - July 9, 2026 - Samsung Bioepis Co., Ltd. announced today that it has entered into a license agreement with Proteina Co., Ltd. to collaborate on a government-supported national R&D initiative aimed at developing AI-based antibody therapeutics.

NewsSamsung Bioepis partnered with Atlatl on Jun 25th '26.By bringing together Samsung Bioepis' global development expertise and ATLATL's innovation ecosystem, we hope to provide early-stage biotech entrepreneurs with the resources and support needed to accelerate innovation and deliver meaningful impact to patients.

NewsSamsung Bioepis Co. partnered with Organon on Jun 18th '26.INCHEON, Korea & KIRKLAND, QC, Canada - June 18, 2026 - Samsung Bioepis and Organon, a global healthcare company with a deep expertise in biosimilars, announced the expansion of their development and commercialization agreement, whereby Organon will obtain commercialization rights in Canada to PYZCHIVA(R), Samsung Bioepis's biosimilar referencing STELARA(R)(ustekinumab).